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ABSTRACT
PGs of the E series are involved in the control of LHRH secretion.
The present experiments were conducted to clarify whether PGI2
(prostacyclin) might be also involved in such a control, using multiple
methodological approaches on immortalized LHRH-secreting neu-
rons. A RT-PCR procedure to detect mouse PGI2 receptor (IP) mes-
senger RNA was first applied, and the results obtained showed the
presence of a specific transcript in two cell lines of immortalized
LHRH neurons (GT1–1 and GN11 cell lines). Receptor binding assays
on membrane preparations from GT1–1 cells showed the presence of
a single specific and saturable class of binding sites (Kd 5 4.6 nM;
10,000 sites/cell) for [3H]iloprost, a stable analog of PGI2. Competition
experiments showed that the binding sites labeled by [3H]iloprost
possess the pharmacological characteristics of IP receptors. In func-
tional studies, PGI2 and its analogs, iloprost and cicaprost, were able
to stimulate LHRH release from the GT1–1 cells with elevated
potencies (EC50 5 0.6–4.3 nM); PGE1 was only slightly less active
(EC50 5 28.5 nM), whereas PGE2, considered the major PG involved
in LHRH secretion, was poorly effective (EC50 5 921 nM). The relative
potencies (EC50) of these compounds in stimulating the intracellular
accumulation of cAMP were in line with their LHRH-releasing
activities.
In conclusion, these results indicate that immortalized LHRH-
secreting neurons express IP receptors through which PGI2 may exert
relevant effects on LHRH release. (Endocrinology 140: 171–177,
1999)
THE PEPTIDE LHRH, synthesized by specific hypotha-lamic neurons, is the major regulator of the secretion of
pituitary gonadotropins. The secretion of LHRH is under the
control of multiple nervous pathways, which involve differ-
ent neurotransmitters, several neuropeptides, steroid hor-
mones, and other neuroactive factors (e.g. PGs, cytokines etc.)
(1–3).
The LHRH system is composed of only a few hundred
neurons, which are not confined to a discrete nucleus but are
distributed as clusters extending from the preoptic to the
anterior hypothalamic regions (4). Such an organization
makes it difficult to determine, by in vivo or ex vivo experi-
ments, whether the different regulatory factors exert their
effects directly on the LHRH-synthesizing neurons or
whether they act via the activation and/or inhibition of other
neuronal systems impinging on the LHRH-secreting neurons
(2).
A promising tool for the investigation of the possible ex-
citatory or inhibitory inputs reaching the LHRH-secreting
neurons is represented by the utilization of immortalized
hypothalamic cell lines, such as GT1 (5) and GN (6) cells.
Among these, GT1 cells have been extensively studied, and
it has been found that they retain many characteristics of
hypothalamic LHRH-secreting neurons, such as a neuronal
morphology, the expression of neuronal markers, an ele-
vated synthesis of the LHRH gene, and the typical pulsatile
secretion of LHRH (7–9). In the last few years, the receptors
for several families of neurotransmitters known to modify
LHRH secretion have been identified on GT1 cells, and the
stimulatory or inhibitory activity of the corresponding li-
gands on LHRH secretion has been documented (8). In par-
ticular, the presence of functional opioid receptors of the
d-type has been ascertained in GT1–1 cells, a subclone of the
GT1 cell line (10). It has also been reported that the activation
of these receptors leads to an inhibition of the release of
LHRH when this is stimulated by either forskolin or PGs (11).
Prostanoids (PGs, tromboxanes, and leukotrienes), which
derive from arachidonic acid metabolism, have been shown
to affect reproductive functions (12–15). Among the various
PGs, PGE2 appears to be the one mainly involved in the
control of LHRH secretion in vivo (16, 17). PGE2 is also able
to induce a significant release of LHRH from GT1 cell line (11,
18, 19), an effect accompanied by an increase in intracellular
cAMP levels and probably mediated by the interaction with
PG receptors of the EP series (see below) (20). However, the
involvement of PGE1 in the control of the secretion of LHRH
in vivo has also been reported (13, 21), and previous results
obtained in the authors’ laboratory have shown that PGE1 is
more potent than PGE2 in stimulating both LHRH release
and cAMP accumulation in GT1–1 cells (10, 11). According
to the most recent classification of the PG receptors (22), PGE1
appears to interact with the putative PGI2 receptor (IP re-
ceptor) with an affinity and a specificity higher than those
found for any other member of the PG receptor family (e.g.
EP).
The strong effect exerted by PGE1 on the release of LHRH
from GT1–1 cells supports the hypothesis that IP receptors
might be present on these cells, and that their activation
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might influence the secretion of LHRH. This hypothesis has
been verified by evaluating the expression of IP receptors in
two immortalized LHRH neuronal cell lines (GT1–1 and
GN11) using RT-PCR. Moreover, GT1–1 cells were used to
perform specific binding assays for IP receptors and to mea-
sure the intracellular accumulation of cAMP and the release
of LHRH after treatment with PGI2, its synthetic analogs
iloprost and cicaprost, PGE1, and PGE2.
Materials and Methods
Chemicals and reagents
PGE1, PGE2, and 3-isobutyl-1-methylxanthine (IBMX) were obtained
from Sigma Chemical Co. (St. Louis, MO); prostacyclin (PGI2) was pur-
chased from Cayman Chemical (Ann Arbor, MI). Iloprost was a gift from
Schering SpA (Segrate, Milan, Italy) and Schering AG (Berlin, Germany),
and cicaprost was provided by U. Habenicht (Schering AG). The stock
solutions of these compounds were made in ethanol and stored at 220
C. The cell culture media and additives were obtained from Biochrom
KG (Berlin, Germany); FBS was obtained from Life Technologies (Grand
Island, NY). [3H]Iloprost (12.7 Ci/mmol) and [g-32P]deoxy-ATP were
purchased from Amersham (Aylesbury, UK). All other analytical grade
reagents were obtained from Merck (Darmstad, Germany) and Sigma
Chemical Co.
Cell cultures
GT1–1 and GN11 cells were provided by R. I. Weiner (San Francisco,
CA) and S. Radovick (Children’s Hospital, Boston, MA), respectively.
The cells were routinely grown in monolayer at 37 C in a humidified CO2
incubator in DMEM containing 1 mm sodium pyruvate, 100 mg/ml
streptomycin, 100 U/ml penicillin, and 10 mg/liter phenol red and
supplemented with 10% FBS. The medium was replaced at 2-day in-
tervals. Subconfluent cells were routinely harvested by trypsinization
and seeded in 57-cm2 dishes (1 3 106 cells). GT1–1 and GN11 cells within
six passages were used throughout the experiments.
RT-PCR analysis
Expression of the specific messenger RNA (mRNA) coding for mouse
IP receptors was tested after nucleic acid amplification, using a PCR
procedure (RT-PCR), of reverse transcribed total RNA extracted from
GT1–1 and GN11 cells. Cultured cells were solubilized in Ultra-Spect
reagent (Biotex Laboratories, Inc., Houston, TX) and processed for total
RNA extraction according to the protocol included in the reagent kit. RT
and PCR were performed using a GeneAmp kit (Perkin Elmer, Branch-
burg, NJ) on 2 mg total RNA from each sample. Samples of total RNA
of adult mouse spleen, known to contain high levels of IP receptor
mRNA (23), were obtained as described for the cells and used as positive
controls. All of the synthetic oligonucleotides, obtained from Pharmacia
Biotech (Uppsala, Sweden), were deduced from the complementary
DNA (cDNA) sequence of the mouse IP receptor (GenBank accession no.
D26157) and verified with the program Amplify (Bill Engels, University
of Wisconsin, Madison, WI). The synthetic oligonucleotides used as
primers were designed to amplify sequence 500-1128 of the IP cDNA,
and their sequences were as follows: upstream primer, 59-CAC.
CCA.TCG.GCC.TTT.GCG.GT-39; and downstream primer, 39-TA.
GTA.CCG.GCA.CAC.GAG.GGA-59. To exclude the presence of con-
tamination with genomic DNA, a parallel set of the RNA samples was
assayed for RT-PCR, but reverse transcriptase was omitted from the
incubation mixture.
The RT conditions were 42 C for 45 min, followed by 5 min at 95 C,
using a final concentration of 1 mm of each deoxy-NTP, 1 U ribonuclease
inhibitor, 2.5 U murine leukemia virus reverse transcriptase, and the
downstream primer in a final volume of 20 ml. The same buffer (50 mm
KCl, 10 mm Tris-HCl, and 2 mm MgCl2) was used for both transcription
and amplification. After this step, 2.5 U Ampli-Taq polymerase and the
upstream primer were added in a final volume of 100 ml. Samples were
amplified by repeated cycles (35 cycles) at 95 C for 1 min, followed by
1 min at 42 C and 1 min at 72 C.
Amplification products were separated by electrophoresis in 2% aga-
rose gel and detected by ethidium bromide staining. The amplified
cDNAs were transferred to blotting membrane (Hybond Nfp, Amer-
sham) by capillary elution in 10 3 SSC (standard saline citrate) and fixed
at 80 C for 2 h. A synthetic antisense oligonucleotide (39-GC.AAG.
GCG.GGT.CGG.ACC.GCC-59 complementary to the sequence 893–912
of IP cDNA) was used as radiolabeled probes in Southern analysis. The
labeling reactions were performed at the free 59-end of the oligoprimers
using T4 DNA polynucleotide kinase, and [g-32P]deoxy-ATP. The
cDNAs fixed on the membrane were incubated at 45 C for 4 h with a
prehybridizing solution; after then, the 32P 59-end-labeled oligonucleo-
tide probes (1 3 106 cpm/ml) were added, and the hybridization reac-
tion was left at 45 C for 16 h. After high stringency washes, the mem-
branes were exposed to x-ray films (Hyperfilm, Amersham).
RT-PCR blanks were performed using distilled water instead of
mRNA and simultaneously subjected to RT-PCR-Southern blotting with
the same reagents and conditions described above; in any of the exper-
iments performed, no specific signal could be obtained, indicating that
no contamination by any reagent occurred in these studies.
Receptor binding assay
[3H]Iloprost (12.7 Ci/mmol), purchased as a solution in organic sol-
vent, was evaporated under nitrogen stream, and the residue was taken
up in 10 mm Tris-HCl, pH 8. PGs stock solutions were diluted in 10 mm
Tris-HCl buffer immediately before use. The program Design (24) was
used to optimize the binding protocols, by selecting the lowest number
of most appropriate concentrations. Homologous iloprost curves were
always performed according to a mixed type protocol, combining both
saturation (the first three concentration points of the curves, 1, 3, and 10
nm) and displacement (the last four concentration points, from 30 nm to
10 mm) curves (25). By effectively combining both saturation and com-
petition protocols in a single curve, one can reach high concentrations
of the ligand without consuming an excessive amount of labeled ligand
(competition part of the curve), yet have adequate radioactivity in the
lower concentration range (saturation part of the curve). Equilibrium
binding studies were performed as previously described (26) with minor
variations. Briefly, GT1–1 membranes (0.1–0.15 mg/sample) were in-
cubated for 5 min at 30 C in 10 mm Tris-HCl, pH 8 (final volume, 100
ml), with 1, 3, and 10 nm [3H]iloprost and unlabeled homologous and
heterologous ligands at the indicated concentrations. Unbound ligand
was separated from bound ligand by rapid vacuum filtration onto glass-
fiber filters (GF/C, Whatman, Clifton, NJ), and the filters were washed
twice with 2 ml ice-cold 10 mm Tris-HCl. Radioactivity was then mea-
sured by liquid scintillation counting (Filter Count, Packard Instruments
Co., Meridien, CT). Nonspecific binding was calculated by Ligand (see
below) as one of the unknown parameters of the model and it ranged
between 25–30% of the total binding of 10 nm [3H]iloprost.
Static culture studies
GT1–1 cells were plated in 24-well plates (0.5 3 106 cells/cm2) and
used after 5 days of culture. All of the samples were assayed for protein
content using a microassay (27) with human serum albumin as a stan-
dard. No variations in total protein per well were detected in any of the
experimental groups (data not shown).
On the day of the experiment, GT1–1 cells were washed with 1 ml
DMEM (prewarmed at 37 C) before addition of the compounds to be
tested, made from 1000-fold concentrated ethanolic solution.
cAMP accumulation. GT1–1 cells were preincubated for 15 min at 37 C in
DMEM containing the phosphodiesterase inhibitor IBMX (0.5 mm). In-
tracellular cAMP accumulation was then measured over a 15-min in-
cubation period at 37 C in DMEM with the various compounds in the
presence of IBMX using a commercial assay kit (Amersham) after eth-
anolic extraction.
LHRH secretion. GT1–1 cells were incubated for 30 min at 37 C in DMEM
with the test compounds. At the end of the incubation period the in-
cubation medium was collected and centrifuged for 5 min at 12,000 rpm,
and the supernatant was stored at 270 C until RIA. The content of LHRH
in the culture medium was determined by RIA using a commercial
antibody (L-8391, Sigma Chemical Co.) and iodinated LHRH (Amer-
sham). Synthetic LHRH (NovaBiochem, Laufefingen, Switzerland) was
used as standard. All samples from the same experiment were run in
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duplicate in the same assay. Inter- and intraassay variations were 9.4%
and 6.6%, respectively. The sensitivity of the assay was 3.9 pg/ml.
Data analysis and statistical evaluation
Analysis of equilibrium ligand binding data were performed by
means of the computer program Ligand (28). Statistical analysis of the
concentration-response curves was performed using the program Allfit
(29), which calculates the lower and upper plateaux, the slope, and the
EC50 and allows the comparison of two or more curves. Selection of the
best fitting model and evaluation of the statistical significance of the
parameters were based on the F test for the extra sum of square principle.
A statistical level of significance with P , 0.05 was accepted. All curves
shown were computer generated.
Results
RT-PCR analysis of the IP receptor transcript in
immortalized LHRH-secreting neurons
The presence of a specific transcript for the IP receptor was
initially investigated in GT1–1 and GN11 immortalized
LHRH-secreting neurons. Figure 1 shows the autoradio-
graphic data obtained after Southern analysis performed on
the amplification products of the RT-PCR. Lane 1 corre-
sponds to an internal control, in which no RNA was added
to the PCR incubation mixture. The presence of a specific
transcript of the expected size (628 bp) was detectable in
RNA samples obtained from mouse spleen (lane 2), which
was used as the positive control (23). The results also show
that a specific amplification of a transcript for the IP receptor
was detected in both GT1–1 (lane 3) and GN11 (lane 4) cells;
no amplification fragments were obtained from RNA sam-
ples when the incubation with RT was omitted (lanes 5 and
6), a fact that excludes contamination of the samples with
genomic DNA.
Further assessment of the biological role(s) of the presence
of IP receptors on immortalized LHRH-secreting neurons
was performed using GT1–1 cells, because these cells rep-
resent a more mature form of LHRH neurons than GN11
cells, which show low levels of expression and release of
LHRH. In addition, many aspect of the physiology of the GT1
cells have been widely characterized (8).
Specific binding of [3H]iloprost to GT1–1 cell
membrane preparations
Binding experiments were then performed on GT1–1 cell
membrane preparations using the stable PGI2 analog [
3H]-
iloprost as the ligand for the IP receptors. The results of
homologous binding curves show that [3H]iloprost bound to
GT1–1 membrane preparations in a dose-dependent manner
(0.1 nm to 10 mm; Fig. 2a). Computer analysis of the results
revealed that [3H]iloprost interacts with a single class of
binding sites with an equilibrium dissociation constant (Kd)
of 4.6 nm and a maximal binding capacity of 85 fmol/mg
protein, which corresponds to about 10,000 sites/cell.
Specificity of [3H]iloprost binding to GT1–1 cell membranes
To verify the specificity of the binding sites labeled by
[3H]iloprost, the competing activity of different unlabeled
PGs was investigated. The results of homologous and het-
erologous competition curves are shown in Fig. 2b. It is
evident that the specific binding of [3H]iloprost on GT1–1 cell
membrane is inhibited by unlabeled PGs in the following
order of potency: iloprost . PGI2 5 PGE1 .. PGE2. In par-
ticular, as summarized in Table 1, unlabeled iloprost com-
petes for the binding of [3H]iloprost with an equilibrium
inhibition constant (Ki) of 4.6 nm; PGI2 and PGE1 are 14- to
20-fold less potent than iloprost (Ki 5 83.8 and 65.8 nm,
respectively). On the other hand, PGE2 exerts a very weak
competition on [3H]iloprost binding, with a potency signif-
icantly smaller (Ki 5 2783.5 nm) than that of either PGI2 or
PGE1. These results indicate the presence of biologically ac-
tive IP receptors specific for PGI2 and its analogs on GT1–1
cell membrane preparations.
Effects of different PGs on intracellular accumulation of
cAMP in GT1–1 cells
It has been extensively reported that IP receptors are pos-
itively coupled to adenylate cyclase, and that PGI2 strongly
stimulates cAMP formation in neural cells (30). A series of
experiments were then performed to verify the effects of
different PGs on the accumulation of intracellular cAMP in
GT1–1 cells. In the experimental conditions adopted in the
FIG. 1. IP receptor transcripts, evidenced by ethidium bromide stain-
ing (upper panel) and Southern blot (lower panel), detected by RT-
PCR in RNA samples extracted from mouse spleen (lane 2) and im-
mortalized hypothalamic neuronal cell lines GT1–1 (lane 3) and GN11
(lane 4). Lanes 5 and 6 represent the reaction products of RNA sam-
ples from GT1–1 and GN11 cells, respectively, not incubated with
reverse transcriptase. The negative control was performed using dis-
tilled water instead of RNA (lane 1; see details in Materials and
Methods).
FIG. 2. Pharmacological characterization of IP receptors present on
GT1–1 cells. a, Scatchard plot representation of the specific binding
of [3H]ilprost to GT1–1 cell membrane preparations. b, Selective in-
hibition of [3H]iloprost-specific binding by unlabeled iloprost (F),
PGI2 (), PGE1 (), and PGE2 (E). The binding isotherms were an-
alyzed by the Ligand program, and the binding parameters Bmax, Kd,
and Ki were determined. The data are representative of two inde-
pendent experiments performed in duplicate.
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present study, the basal level of cAMP was 110 pg/mg total
protein.
The dose-response curves obtained in these experiments
are reported in Fig. 3; because of the differences observed in
maximal responses (see below), the curves are represented as
percent values. It has been found that PGI2 as well as its
synthetic agonists iloprost and cicaprost are similarly potent
in stimulating cAMP accumulation in GT1–1 cells and more
potent than PGE1 and PGE2. The potencies of the different
substances are reported in Table 2; it is evident that iloprost
induces a sustained accumulation of cAMP with an EC50 of
0.48 nm; PGI2 and its other stable analog cicaprost are slightly
less potent and stimulate cAMP formation with similar po-
tencies (EC50 1.08 and 1.28 nm, respectively). PGE1 and PGE2
are far less potent than PGI2, with EC50, of 46.8 and 1216.8 nm.
Table 2 also shows that the compounds under study exert
different maximal responses on cAMP formation. This pa-
rameter corresponds to the response at the “infinite” dose of
each compound, as calculated by the Allfit program using
absolute values. Iloprost appears to be the most efficient
agent, inducing a 49-fold accumulation of cAMP over basal
levels. PGI2 and cicaprost show similar elevated maximal
activities (33- and 38-fold, respectively). PGE1 and PGE2 pos-
sess an efficiency significantly lower than those of PGI2 and
its analogs, showing a maximal cAMP increase correspond-
ing, respectively, to 21 and 8 times the basal levels.
Effects of different PGs on secretion of LHRH from
GT1–1 cells
To verify whether the activation of cAMP-mediated in-
tracellular pathways elicited by agents stimulating the IP
receptor plays a physiological role in GT1–1 cells, the effects
of various PGs on the release of LHRH were subsequently
investigated. The results are summarized in Fig. 4 and Table
3. The evaluation of LHRH accumulation in the culture me-
dium under the effects of different PGs shows that cicaprost
exerts the highest potency as an LHRH secretagogue (EC50
5 0.6 nm), followed by iloprost and PGI2, which are able to
stimulate LHRH release from GT1–1 cells with similar po-
tencies (EC50 5 4.3–4.7 nm). PGE1 is less potent than PGI2 and
its stable analogs (EC50 5 28.5); PGE2 shows the lowest po-
tency (215 times less than that of PGI2; EC50 5 921 nm). The
maximal stimulation of LHRH release evoked by the various
PGs is comparable and equivalent to an increase of 1- to
1.5-fold the basal levels measured in the medium of un-
stimulated cells (Table 3).
Discussion
The present study provides the first evidence of the pres-
ence of specific prostacyclin receptors (IP receptors) on im-
mortalized hypothalamic LHRH-producing neurons. The re-
sults reported here also show the presence of a specific
transcript related to a sequence of the cloned mouse IP re-
ceptor (23) in two different cell lines of LHRH neurons,
GT1–1 and GN11 cells. The presence of an IP transcript in
both cell lines suggests that the expression of IP receptors is
conserved among LHRH-secreting neurons and strongly
supports the possibility that hypothalamic LHRH neurons in
situ might also express IP receptors.
The experiments devoted to the clarification of the binding
characteristics of the IP receptors and their possible physi-
ological roles were performed in GT1 cells, as many mech-
anisms controlling LHRH release have been well studied in
this cell line (8, 31, 32). First, high affinity (Kd 5 4.6 nm)
binding sites for [3H]iloprost (23, 33) were found in crude
GT1–1 cell membrane preparations. The binding character-
istics of [3H]iloprost to GT1–1 cells and its specificity are in
agreement with those reported for the same tracer when
tested on other cells and tissues (33–36) as well as on Chinese
hamster ovary cells transfected with the mouse IP receptor
FIG. 3. Dose-related effect of PGI2 (), its synthetic analogs iloprost
(F) and cicaprost (L), PGE1 (), and PGE2 (E) on the intracellular
accumulation of cAMP in GT1–1 cells. Cells were incubated for 30 min
with IBMX (0.5 mM) in serum-free medium, PGs were then added for
the last 15 min of culture. Results are expressed as a percentage of
the maximal effect obtained from each compound determined from
two independent experiments using quadruplicate wells for each de-
termination.
TABLE 2. Effects of different PGs on the intracellular accumulation
of cAMP in GT1-1 cells
Compounds EC50 (nM)
Maximal efficacy
cAMP
(pmol/ml)a
Fold induction
(vs. control)
Control 0.72 6 0.1 1.0
Iloprost 0.48 6 0.05 35.6 6 6.0 49.1
PGI2 1.08 6 0.31 28.0 6 11.6 38.9
Cicaprost 1.28 6 0.24 24.2 6 7.2 33.6
PGE1 46.80 6 18.06
b 15.6 6 4.3b 21.7
PGE2 1216.80 6 187.91
b 6.12 6 4.3b 8.5
Values are expressed as the mean 6 SD.
a cAMP levels obtained at the “infinite” dose of each compound and
corresponding to the upper plateau of the dose-response curve ob-
tained using absolute values.
b P , 0.05, significant vs. PGI2 by Allfit analysis.
TABLE 1. Competing activities of different PGs on the binding of
[3H]iloprost on GT1-1 cell membrane preparations
Competitor Ki (nM)
Iloprost 4.6 6 0.8
PGE1 65.8 6 5.9
PGI2 83.8 6 7.6
PGE2 2783.5 6 759.9
Values are expressed as calculated Ki values 6 SD.
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gene (23). Selective competition experiments performed with
several PGs further confirm that the binding sites labeled by
[3H]iloprost on GT1–1 cells belong to the IP class of PG
receptors (22, 23).
It is well known that IP receptors are positively coupled to
adenylyl cyclase and that their activation leads to an accu-
mulation of cAMP in several cells and tissues (37). The results
presented have clearly shown that PGI2 and its analogs,
iloprost and cicaprost, are strong stimulators of cAMP ac-
cumulation in GT1–1 cells, whereas PGE2 possesses the lower
potency. These data are consistent with previous findings
showing that prostacyclin stimulates the intracellular accu-
mulation of cAMP in nonneural and neural cells (23, 30, 38)
and indicate, in addition, that this effect is induced via the
activation of IP receptors.
The low efficacy of PGE2 on cAMP accumulation was
surprising in view of the preliminary identifications in GT1–1
cells of transcripts for the EP1, EP2, and EP3 PG receptors (20)
to which PGE2 preferentially binds (22). However, the pres-
ence of biologically active receptors of the EP series in GT1–1
cells has yet to be demonstrated by functional or binding
experiments.
The functional role of IP receptors detected on GT1–1 cells
has been further confirmed in the present study by the find-
ing that prostacyclin and its analogs stimulate the release of
LHRH in a dose-dependent manner. In general, this effect
reflects the pharmacological profile of the activation of the IP
receptors as measured in the other experiments here de-
scribed (e.g. binding studies and cAMP accumulation). How-
ever, even though there is a good correlation between the
potencies (EC50) and the efficacies of the various PGs in
stimulating cAMP production, this is less evident when
cAMP production and LHRH release are analyzed. First,
PGI2, iloprost, and cicaprost stimulated cAMP accumulation
with similar potencies; however, the latter compound
proved to be much more potent than PGI2 and iloprost in
stimulating LHRH release. In this context, it is important to
remember that the release of LHRH from GT1 cells is under
the control of various signaling pathways and that each of
these may operate via multiple steps (PKA, PKC, cGMP, ion
channels, etc.) (8, 31, 32). It has also been reported that PGE2-
stimulated LHRH release involves intracellular calcium (39).
Because of these considerations, the apparent divergence in
the potencies of cicaprost on cAMP accumulation and LHRH
release may be indicative of the activation of signaling sys-
tems, other than cAMP (40), induced by cicaprost in GT1–1
cells.
Another point that deserves some comment is the fact that
the PGs considered in the present study stimulate cAMP
accumulation with different efficacies even if all of the com-
pounds tested show similar maximal LHRH-releasing activ-
ity. One possible explanation of this quantitative discrepancy
may be that the increase in intracellular levels of cAMP
induced by the less effective agent (i.e. PGE2) is already
sufficient to totally discharge the pool of releasable LHRH
present in GT1–1 cells. On the other hand, the elevated for-
mation of cAMP induced by PGI2 and its analogs might
subserve additional cellular functions [for instance, the mor-
phological differentiation of the cells we observed in pre-
liminary experiments (Maggi, R., et al., in preparation)].
If one accepts that immortalized hypothalamic neurons
represent a good model for study of the physiological func-
tions of LHRH-producing neurons (8, 9), the obvious con-
clusion derived from these results is that the selective acti-
vation of IP receptors (by PGI2 or by PGE1) may play an
important role in the control of LHRH secretion.
The physiological relevance of the presence of IP receptors
in and around the LHRH neuronal system is supported by
the identification of similar amounts of PGE2 and 6-cheto-
PGF1a, the main metabolite of PGI2, in extracts of rat median
eminence (41). In addition, it has been reported that estro-
gens may affect the production of PGI2 in different in vivo and
in vitro systems (42).
The data reported here do not permit identification of the
possible source of the PGI2 interacting with the IP receptors
present on hypothalamic LHRH neurons; nevertheless, some
hypotheses may be proposed. The first takes into consider-
ation a possible autocrine function of PGI2. It has been found
that LHRH-liberating agents (e.g. endothelin) facilitate the
release of LHRH from GT1 cells via stimulation of the pro-
FIG. 4. Dose-related effect of PGI2 (), its synthetic analogs iloprost
(F) and cicaprost (L), PGE1 (), and PGE2 (E) on the release of LHRH
from GT1–1 cells. Cells were incubated for 30 min with PGs, and the
content of LHRH released in the culture medium was measured by
RIA. Results are expressed as a percentage of the maximal effect
obtained from each compound determined from three independent
experiments using quadruplicate wells for each determination.
TABLE 3. Effects of different PGs on the secretion of LHRH from
GT1-1 cells
Compounds EC50 (nM)
Maximal efficacy
LHRH
(pg/ml)a
Fold induction
(vs. control)
Control 94.4 6 10.4 1.0
Cicaprost 0.6 6 0.4b,c 185.6 6 19.8 1.9
PGI2 4.3 6 1.7 225.2 6 28.4 2.4
Iloprost 4.7 6 1.8 190.4 6 21.5 2.0
PGE1 28.5 6 4.7
b 230.9 6 18.5 2.4
PGE2 921.8 6 178.8
b 209.2 6 16.9 2.2
Values are expressed as the mean 6 SD.
a LHRH levels obtained at the “infinite” dose of each compound and
corresponding to the upper plateau of the dose-response curve ob-
tained using absolute values.
b P , 0.05, significant vs. PGI2, by Allfit analysis.
c P , 0.05, significant vs. iloprost, by Allfit analysis.
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duction of arachidonic acid derivatives (18). It is then pos-
sible that PGI2 might be produced by the LHRH neurons
themselves in response to stimulatory signals. A second hy-
pothesis is derived from the recently discovered involvement
of glial cells in the control of LHRH release (43, 44). In
particular, it has been observed that transforming growth
factor-a may stimulate the production and release of PGE2
from astrocytes impinging on the LHRH neurons; in turn,
this and other PGs would induce LHRH release (43). Finally,
it may be recalled that at the level of the median eminence,
LHRH axons are in close association with the endothelium
of the pituitary portal vessels, and that some vasoactive
factors released by the blood vessels (e.g. endothelin and
nitric oxide) have been found to affect the release of LHRH
(18, 45). It is then attractive to hypothesize that PGI2, which
is also produced by the vascular endothelium, might create
an additional functional link between the portal vessels and
the hypophysiotropic neurons, leading to a synergizing
effect.
In conclusion, the present results indicate that not only
PGE2, but also PGs acting on the IP receptors, may participate
in the activation of LHRH release. As it is known that PGs
represent the final mediator in many biological systems, the
present results prompt additional studies on the reciprocal
interactions between the most classical neurotransmitter sys-
tems known to induce the release of LHRH (norepinephrine,
epinephrine, dopamine, nitric oxide, histamine, excitatory
amino acids, etc.) and the ubiquitous system of arachidonic
acid derivatives.
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